<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01363661</url>
  </required_header>
  <id_info>
    <org_study_id>MEDCOR 2011</org_study_id>
    <secondary_id>2011-000190-31</secondary_id>
    <nct_id>NCT01363661</nct_id>
  </id_info>
  <brief_title>Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris</brief_title>
  <acronym>MEDCOR</acronym>
  <official_title>Double-blind Parallel Placebo-controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction in Patients With Stable Angina Pectoris Undergoing a Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Therabel Pharma SA/NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Therabel Pharma SA/NV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Molsidomine used as an add-on treatment on standard care therapy should be superior to
      placebo used also as an add-on treatment on standard care therapy on improving the
      endothelial function (endothelium score measured by reactive hyperemia - peripheral arterial
      tonometry [RH-PAT]) after 12 months of treatment in patients with stable angina patients and
      undergoing elective percutaneous coronary intervention.

      The study will be double-blind, parallel-group, randomised, multicentre, sequential,
      placebo-controlled study.

      The device used to determine RH-PAT will be EndoPAT. Duration of the treatment = one year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Data Steering Committee (DSC) will blindly assess the recruitment rate, the variability of
      RH-PAT within and between centres, and the safety on a regular basis.

      Sequential approach:

        -  In the first phase (Phase A) of the study, 180 patients will be enrolled in order to get
           at least 50 completers after 12 months of treatment. A statistical evaluation of the
           primary endpoint will be done by an Independent Biostatistician after approximately 50
           patients have completed the study in accordance with the protocol.

        -  The results will be examined by an Independent Data Monitoring Committee (IDMC)which
           will assess the results and advise the sponsor as to:

             1. Continue the study if the primary objective has not been achieved but the
                difference between the two groups is at least 10% (difference considered clinically
                significant). In this case, the sample size will be recalculated by the Independent
                Biostatistician taking into account actual difference and variability. The total
                number of patients to be enrolled in addition in Phase B will be calculated with
                precision. Depending on IDMC recommendations, the number of investigating centres
                will be increased or not for Phase B. If the right number of patients has already
                been enrolled, Phase B will not start. The study will stop when all enrolled
                patients have completed the one-year treatment period.

             2. Terminate the study, if the difference between the two groups is less than 10%.

             3. Consider the study as completed if the primary endpoint has been achieved.

      Treatment allocation: Balanced allocation between molsidomine and placebo (1:1) with a
      stratification for consumption of statins, for the type of stent (drug-eluting stent or
      bare-metal) and for consumption of angiotensin-converting enzyme inhibitors (ACEIs).

      Data collection: Electronic Case Report Form (eCRF).

      Duration of study: A minimum of 30 months (16 months for inclusion and 14 months for the
      study) for Phase A.

      Number of investigational centres:

        -  Up to 10 centres for Phase A

        -  To be determined for Phase B based on Phase A.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change Versus Baseline in the Score of the EndoPAT in the Two Groups After One Year of Treatment (Month 12).</measure>
    <time_frame>12 months</time_frame>
    <description>The results are expressed mean relative change (%) between month 12 and baseline. A positive result means improvement in the score of the EndoPAT between baseline and month 12. It could be considered as a surrogate of a decrease of the endothelial dysfunction. A negative percentage means the inverse. The are no fixed limits to the scale. The minimum observed was -275% and the maximum observed was +4200%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change Versus Baseline in the Score of the EndoPAT in the Two Groups After Six Months of Treatment (Month 6).</measure>
    <time_frame>Month 6</time_frame>
    <description>The results are expressed mean relative change (%) between month 6 and baseline. A positive result means improvement in the score of the EndoPAT between baseline and month 6. It could be considered as a surrogate of a decrease of the endothelial dysfunction. A negative percentage means the inverse. The are no fixed limits to the scale. The minimum observed was -200% and the maximum observed was +6100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Versus Baseline in the Augmentation Index in the Two Groups After Six and Twelve Months of Treatment (Months 6 and 12).</measure>
    <time_frame>Month 6 and Month 12</time_frame>
    <description>The results are expressed mean relative change (%) between month 6 or month 12, and baseline. A positive result means improvement in the augmentation index between baseline and month 6 or month 12. It could be considered as a surrogate of a decrease of the arterial stiffness. A negative percentage means the inverse. The are no fixed limits to the scale. At month 6,the minimum observed was -139% and the maximum observed was +1600%.At month 12, the minimum observed was -524% and the maximum observed was +1600%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Versus Baseline in Some Specific Endothelial Biomarkers After Twelve Months of Treatment (Month 12).</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Serious Cardiovascular Events (SCEs) in the Two Groups After Twelve Months of Treatment (Month 12).</measure>
    <time_frame>Month 12</time_frame>
    <description>Sum of the events collected during 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AEs and SAEs in the Two Groups After Twelve Months of Treatment (Month 12).</measure>
    <time_frame>Month 12</time_frame>
    <description>Sum of the events collected during 12 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Stable Angina Pectoris</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Molsidomine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coruno (molsidomine 16 mg tablet; per os; once daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (16 mg tablet; once a day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coruno</intervention_name>
    <description>Molsidomine 16 mg tablet, per os, once a day</description>
    <arm_group_label>Molsidomine</arm_group_label>
    <other_name>Molsidomine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (16 mg tablet, per os; once-daily)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged at least 18 years.

          -  No treatment with molsidomine and/or long-acting nitrates (oral or patches) for more
             than 48 hours during the month preceding percutaneous coronary intervention (PCI) and
             no treatment with these same drugs within 3 days before PCI.

          -  Patients who the investigator believes that they and/or their Legally Acceptable
             Representative (LAR) can and will comply with the requirements of the protocol.

          -  Written informed consent from the patient or from the LAR.

          -  Patients who underwent PCI for stable angina pectoris one month prior to the start of
             the study.

          -  Patients presenting endothelial dysfunction at Month 0 (score of the Endo-PAT &lt;0.40).

        Exclusion Criteria:

          -  Pre-menopausal women.

          -  Patient with a clinically-active malignancy.

          -  Known major renal insufficiency or known significant hepatic insufficiency.

          -  History of psychological disorder, mental dysfunction, alcohol or drug abuse or any
             other factor which might interfere with the ability to cooperate in the study.

          -  Participation in another clinical trial which has not yet reached its primary endpoint
             or with the same primary endpoint during the previous month.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject will be exposed to an investigational or a
             non-investigational product (vaccine, drug or device).

          -  Hypersensitivity to molsidomine or to one of its excipients.

          -  Peri-procedural infarction: creatine kinase-muscle/brain (CK-MB) &gt;3 times the upper
             reference limit.

          -  Clinically significant abnormal pre-PCI CK-MB and troponin: any elevation above the
             upper reference limit.

          -  Intolerance to galactose, deficiency in Lapp lactase or glucose-galactose
             malabsorption.

          -  Left ventricular insufficiency (New York Heart Association [NYHA] class III or IV)
             with an ejection fraction &lt;35%.

          -  Acute circulatory insufficiency (e.g. cardiogenic shock).

          -  Hypotension: systolic blood pressure &lt;100 mmHg and/or diastolic blood pressure &lt;70
             mmHg.

          -  Atrial fibrillation

          -  Acute myocardial infarction during the preceding month.

          -  Unsuccessful PCI: residual stenosis of at least 50%.

          -  Patient taking phosphodiesterase-5 inhibitors, such as sildenafil (Viagra®),
             vardenafil (Levitra®) and tadalafil (Cialis®)

          -  Patient taking nebivolol (Nobiten®)

          -  Patient taking ibuprofen + L-arginine as excipient (Spidifen®)

          -  Patient meeting any contraindication(s) from Coruno®. Please refer to Coruno®
             (molsidomine 16 mg o.d.)Summary of Product Characteristics (SPC).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuele Barbato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Center, Onze Lieve Vrouw Ziekenhuis Aalst</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Barbato E, Herman A, Benit E, Janssens L, Lalmand J, Hoffer E, Chenu P, Guédès A, Missault L, Pirenne B, Cardinal F, Vercauteren S, Wijns W. Double-blind parallel placebo-controlled study to evaluate the effect of molsidomine on the endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: the MEDCOR Trial. J Cardiovasc Transl Res. 2014 Mar;7(2):226-31. doi: 10.1007/s12265-013-9513-9. Epub 2013 Oct 19.</citation>
    <PMID>24142804</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2011</study_first_submitted>
  <study_first_submitted_qc>May 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2011</study_first_posted>
  <results_first_submitted>September 15, 2014</results_first_submitted>
  <results_first_submitted_qc>September 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2014</results_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>angina pectoris</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molsidomine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The drop-out rate post-PCI was high (&gt;60%) mainly because the Endoscore was frequently above the pre-defined threshold post-PCI, attesting of the absence of endothelial dysfunction. Post-randomization drop-out rate was also high, 25% of patients being lost between randomization and month 12, mainly for non-serious adverse events.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Molsidomine</title>
          <description>Coruno (molsidomine 16 mg tablet; per os; once daily)
Coruno: Molsidomine 16 mg tablet, per os, once a day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (16 mg tablet; once a day)
Placebo: Placebo (16 mg tablet, per os; once-daily)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This population corresponded to the per protocol cohort: patients who had been randomized to placebo or molsidomine and who had completed the study in accordance with the protocol.</population>
      <group_list>
        <group group_id="B1">
          <title>Molsidomine</title>
          <description>Coruno (molsidomine 16 mg tablet; per os; once daily)
Coruno: Molsidomine 16 mg tablet, per os, once a day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo (16 mg tablet; once a day)
Placebo: Placebo (16 mg tablet, per os; once-daily)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="10.2"/>
                    <measurement group_id="B2" value="64.1" spread="9.9"/>
                    <measurement group_id="B3" value="63.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change Versus Baseline in the Score of the EndoPAT in the Two Groups After One Year of Treatment (Month 12).</title>
        <description>The results are expressed mean relative change (%) between month 12 and baseline. A positive result means improvement in the score of the EndoPAT between baseline and month 12. It could be considered as a surrogate of a decrease of the endothelial dysfunction. A negative percentage means the inverse. The are no fixed limits to the scale. The minimum observed was -275% and the maximum observed was +4200%.</description>
        <time_frame>12 months</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Molsidomine</title>
            <description>Coruno (molsidomine 16 mg tablet; per os; once daily)
Coruno: Molsidomine 16 mg tablet, per os, once a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (16 mg tablet; once a day)
Placebo: Placebo (16 mg tablet, per os; once-daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Change Versus Baseline in the Score of the EndoPAT in the Two Groups After One Year of Treatment (Month 12).</title>
          <description>The results are expressed mean relative change (%) between month 12 and baseline. A positive result means improvement in the score of the EndoPAT between baseline and month 12. It could be considered as a surrogate of a decrease of the endothelial dysfunction. A negative percentage means the inverse. The are no fixed limits to the scale. The minimum observed was -275% and the maximum observed was +4200%.</description>
          <population>Per protocol population</population>
          <units>Relative change versus baseline (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330.60" spread="1014.98"/>
                    <measurement group_id="O2" value="164.08" spread="433.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Versus Baseline in the Score of the EndoPAT in the Two Groups After Six Months of Treatment (Month 6).</title>
        <description>The results are expressed mean relative change (%) between month 6 and baseline. A positive result means improvement in the score of the EndoPAT between baseline and month 6. It could be considered as a surrogate of a decrease of the endothelial dysfunction. A negative percentage means the inverse. The are no fixed limits to the scale. The minimum observed was -200% and the maximum observed was +6100%.</description>
        <time_frame>Month 6</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Molsidomine</title>
            <description>Coruno (molsidomine 16 mg tablet; per os; once daily)
Coruno: Molsidomine 16 mg tablet, per os, once a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (16 mg tablet; once a day)
Placebo: Placebo (16 mg tablet, per os; once-daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Change Versus Baseline in the Score of the EndoPAT in the Two Groups After Six Months of Treatment (Month 6).</title>
          <description>The results are expressed mean relative change (%) between month 6 and baseline. A positive result means improvement in the score of the EndoPAT between baseline and month 6. It could be considered as a surrogate of a decrease of the endothelial dysfunction. A negative percentage means the inverse. The are no fixed limits to the scale. The minimum observed was -200% and the maximum observed was +6100%.</description>
          <population>Per protocol population</population>
          <units>Relative change versus baseline (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361.98" spread="1248.52"/>
                    <measurement group_id="O2" value="326.26" spread="1155.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Versus Baseline in the Augmentation Index in the Two Groups After Six and Twelve Months of Treatment (Months 6 and 12).</title>
        <description>The results are expressed mean relative change (%) between month 6 or month 12, and baseline. A positive result means improvement in the augmentation index between baseline and month 6 or month 12. It could be considered as a surrogate of a decrease of the arterial stiffness. A negative percentage means the inverse. The are no fixed limits to the scale. At month 6,the minimum observed was -139% and the maximum observed was +1600%.At month 12, the minimum observed was -524% and the maximum observed was +1600%.</description>
        <time_frame>Month 6 and Month 12</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Molsidomine</title>
            <description>Coruno (molsidomine 16 mg tablet; per os; once daily)
Coruno: Molsidomine 16 mg tablet, per os, once a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (16 mg tablet; once a day)
Placebo: Placebo (16 mg tablet, per os; once-daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Change Versus Baseline in the Augmentation Index in the Two Groups After Six and Twelve Months of Treatment (Months 6 and 12).</title>
          <description>The results are expressed mean relative change (%) between month 6 or month 12, and baseline. A positive result means improvement in the augmentation index between baseline and month 6 or month 12. It could be considered as a surrogate of a decrease of the arterial stiffness. A negative percentage means the inverse. The are no fixed limits to the scale. At month 6,the minimum observed was -139% and the maximum observed was +1600%.At month 12, the minimum observed was -524% and the maximum observed was +1600%.</description>
          <population>Per protocol population</population>
          <units>Relative change versus baseline (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.07" spread="437.38"/>
                    <measurement group_id="O2" value="96.35" spread="323.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.57" spread="470.39"/>
                    <measurement group_id="O2" value="95.13" spread="290.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Versus Baseline in Some Specific Endothelial Biomarkers After Twelve Months of Treatment (Month 12).</title>
        <time_frame>Month 12</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Molsidomine</title>
            <description>Coruno (molsidomine 16 mg tablet; per os; once daily)
Coruno: Molsidomine 16 mg tablet, per os, once a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (16 mg tablet; once a day)
Placebo: Placebo (16 mg tablet, per os; once-daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Change Versus Baseline in Some Specific Endothelial Biomarkers After Twelve Months of Treatment (Month 12).</title>
          <population>Per protocol population</population>
          <units>Relative change versus baseline (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Endothelial microparticles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40" spread="75"/>
                    <measurement group_id="O2" value="-40" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet microparticles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="101"/>
                    <measurement group_id="O2" value="-23" spread="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte microparticles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39" spread="83"/>
                    <measurement group_id="O2" value="-37" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sICAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" spread="51"/>
                    <measurement group_id="O2" value="6" spread="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="43"/>
                    <measurement group_id="O2" value="-25" spread="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hs-CRP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50" spread="237"/>
                    <measurement group_id="O2" value="-35" spread="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MOX-LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="80"/>
                    <measurement group_id="O2" value="41" spread="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPO antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="19"/>
                    <measurement group_id="O2" value="-32" spread="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPO activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43" spread="51"/>
                    <measurement group_id="O2" value="8" spread="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPO activity/antigen ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42" spread="60"/>
                    <measurement group_id="O2" value="7" spread="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Serious Cardiovascular Events (SCEs) in the Two Groups After Twelve Months of Treatment (Month 12).</title>
        <description>Sum of the events collected during 12 months.</description>
        <time_frame>Month 12</time_frame>
        <population>Intention-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Molsidomine</title>
            <description>Coruno (molsidomine 16 mg tablet; per os; once daily)
Coruno: Molsidomine 16 mg tablet, per os, once a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (16 mg tablet; once a day)
Placebo: Placebo (16 mg tablet, per os; once-daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Serious Cardiovascular Events (SCEs) in the Two Groups After Twelve Months of Treatment (Month 12).</title>
          <description>Sum of the events collected during 12 months.</description>
          <population>Intention-to-treat population</population>
          <units>Number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of AEs and SAEs in the Two Groups After Twelve Months of Treatment (Month 12).</title>
        <description>Sum of the events collected during 12 months.</description>
        <time_frame>Month 12</time_frame>
        <population>Intention-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Molsidomine</title>
            <description>Coruno (molsidomine 16 mg tablet; per os; once daily)
Coruno: Molsidomine 16 mg tablet, per os, once a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (16 mg tablet; once a day)
Placebo: Placebo (16 mg tablet, per os; once-daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of AEs and SAEs in the Two Groups After Twelve Months of Treatment (Month 12).</title>
          <description>Sum of the events collected during 12 months.</description>
          <population>Intention-to-treat population</population>
          <units>Number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Molsidomine</title>
          <description>Coruno (molsidomine 16 mg tablet; per os; once daily)
Coruno: Molsidomine 16 mg tablet, per os, once a day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (16 mg tablet; once a day)
Placebo: Placebo (16 mg tablet, per os; once-daily)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Sleep study</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Melanoma recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Too limited sample size. Huge variability in all measurements. High drop-out rate. Add-on treatment was a challenge to demonstrate a difference between Coruno and placebo.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jacques Bruhwyler, Project Manager</name_or_title>
      <organization>ECSOR</organization>
      <phone>3267444093</phone>
      <email>Jacques.Bruhwyler@ecsor.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

